Joel Fruendt: Thanks, Tom. How humanity is currently responding to too many rodents is not working. With many decades of effort and traditional responses, the public health concerns and risks keep rising. There’s also a growing realization that there’s too much collateral damage in this war on rodents, as evidenced by California’s adoption of the Ecosystems Protection Act, which banned under many circumstances the four major second-generation anticoagulant rodenticides, commonly used in rodent pest control. These tailwinds are all in our favor. And most importantly, we are executing. We are delivering against our success imperatives by selling better, improving our products and offering the customers more choices. As was stated last quarter, products that can be paradigm changing don’t come along very often.
But when they do, they have an opportunity to change the way things have been done for generations. I believe we have the type of opportunity by leading the way in fertility control for animal pest populations. I thank you all for your continued support. And with that, let me now turn it over for any questions.
Operator: [Operator Instructions]
Robert Blum: Amy, this is Robert here. While we wait to see if there’s any questions from the live dialers here, we did have one emailed question that I wanted to make sure we could pose to management. I guess to Joel or Tom here. The question is, congratulations on your new product. It sounds like you are very excited by it. But from an investor standpoint, how big is it really?
Joel Fruendt: I’ll take that one, Tom. It is quite literally a game changer. For one, most of the pest control market prefers a non-liquid product to best fit in their workflow. But they understand the need to add fertility control to their service offerings. Two, this is truly a consumer-friendly product and can be sold on the shelves of your local hardware store, agricultural supply store or your favorite e-commerce portal. Three, Evolve may start with rats, but follow-on products for other species can be pursued immediately. And then finally, many other countries have similar expedited approvals to the EPA’s 25B. For example, we can start the process in Canada immediately. This is particularly timely. British Columbia has recently banned the use of second-generation anticoagulant rodenticides, as did California.
And they definitely need a fertility control to fill the gap. So from an investor standpoint, this means more press, more revenue and a realistic shot at profitability by 2025.
Robert Blum: Perfect, Joel. Thank you for that. Amy, I’ll turn it back over to you.
Operator: [Operator Instructions] This concludes our question-and-answer session. I would now like to turn the conference back over to management for any closing remarks.
Joel Fruendt: Thank you all for attending and we look forward to our Q4 results after the first part of the year.
Operator: Conference is now concluded. Thank you for attending today’s presentation. You may now disconnect.
